MindMerge Advisors, in partnership with Endeavor Advisory Group, delivers premier M&A advisory, financing, and strategic solutions for the psychedelic pharmaceutical sector.
MindMerge Advisors, in partnership with Endeavor Advisory Group, delivers premier M&A advisory, financing, and strategic solutions for consolidating the psychedelic pharmaceutical sector.
MindMerge Advisors, in partnership with Endeavor Advisory Group, delivers premier M&A advisory, financing, and strategic solutions for the psychedelic pharmaceutical sector.
Transforming mental health innovation into market leadership.
Backing revolutionary mental health treatments through responsible M&A.
Backing the revolution in mental health treatment through responsible M&A.
Experienced Leadership in Psychedelic Pharma
Experienced Leadership in Psychedelic Pharma
Our members have founded, exited and overseen the mergers and acquisitions of psychedelic pharma companies. We have decades of experience in the field of pychedelics, and intimate knowledge of M&A in the sector
Our members have founded, exited and overseen the mergers and acquisitions of psychedelic pharma companies. We have decades of experience in the field of pychedelics, and intimate knowledge of M&A in the sector
Partnership with Endeavor Advisory Group
Partnership with Endeavor Advisory Group
Endeavor Advisory Group is a global investment bank with over 30 years of M&A experience and a recent mandate of $11.75b.
Endeavor Advisory Group is a global investment bank with over 30 years of M&A experience and a recent mandate of $11.75b.
Vision for growth
Vision for growth
As your M&A partner advancing psychedelic pharmaceutical consolidation, we bring a strong network, proven track record, and unique insight into unlocking the potential of the field through consolidation.
As your M&A partner advancing psychedelic pharmaceutical consolidation, we bring a strong network, proven track record, and unique insight into unlocking the potential of the field through consolidation.
Meet Our Team.
Meet Our Team
Leaders in drug discovery & innovation.
Meet Our Team.
Leaders in drug discovery & innovation.
Alex Belser, PhD
Former Chief Clinical Officer at Cybin Inc. and co-founder/Chief Clinical Officer of Adelia Therapeutics (exited to CYBN), Alex possesses extensive experience in psychedelic science and drug discovery.
He is recognized for his pioneering work in advancing psychedelic therapies for mental health and driving innovation in research and clinical applications.
Alex’s leadership fosters collaboration and progress in the understanding and development of transformative therapies.
Alex Belser, PhD
Former Chief Clinical Officer at Cybin Inc. and co-founder/Chief Clinical Officer of Adelia Therapeutics (exited to CYBN), Alex possesses extensive experience in psychedelic science and drug discovery.
He is recognized for his pioneering work in advancing psychedelic therapies for mental health and driving innovation in research and clinical applications.
Alex’s leadership fosters collaboration and progress in the understanding and development of transformative therapies.
Alex Belser, PhD
Former Chief Clinical Officer at Cybin Inc. and co-founder/Chief Clinical Officer of Adelia Therapeutics (exited to CYBN), Alex possesses extensive experience in psychedelic science and drug discovery.
He is recognized for his pioneering work in advancing psychedelic therapies for mental health and driving innovation in research and clinical applications.
Alex’s leadership fosters collaboration and progress in the understanding and development of transformative therapies.
Bill Brennan, PhD
A leading consultant and expert in psychedelic clinical trials, Bill has built a proven track record in designing and overseeing clinical programs to advance novel therapies.
His expertise brings critical regulatory and operational insights to the team, ensuring best practices in trial design and execution.
Bill’s vision and operational excellence accelerate the development and approval of groundbreaking psychedelic treatments.
Bill Brennan, PhD
A leading consultant and expert in psychedelic clinical trials, Bill has built a proven track record in designing and overseeing clinical programs to advance novel therapies.
His expertise brings critical regulatory and operational insights to the team, ensuring best practices in trial design and execution.
Bill’s vision and operational excellence accelerate the development and approval of groundbreaking psychedelic treatments.
Bill Brennan, PhD
A leading consultant and expert in psychedelic clinical trials, Bill has built a proven track record in designing and overseeing clinical programs to advance novel therapies.
His expertise brings critical regulatory and operational insights to the team, ensuring best practices in trial design and execution.
Bill’s vision and operational excellence accelerate the development and approval of groundbreaking psychedelic treatments.
Michael Palfreyman, PhD
With more than 40 years of experience in biotech and pharma, Michael G. Palfreyman specializes in drug discovery, translational R&D, and early clinical development.
He is the holder of 53 patents and 150+ publications, and has led multiple companies to successful exits and partnerships. In the psychedelic sector, Mike was co-founder and COO of Adelia Therapeutics (sold to CYBN) and a co-founder of Amorsa Therapeutics, which partnered with Johnson & Johnson to develop novel, ketamine based therapeutics for treatment resistant depression.
Michael’s scientific rigor and business acumen are foundational to the team’s ongoing innovation and growth.
Michael Palfreyman, PhD
With more than 40 years of experience in biotech and pharma, Michael G. Palfreyman specializes in drug discovery, translational R&D, and early clinical development.
He is the holder of 53 patents and 150+ publications, and has led multiple companies to successful exits and partnerships. In the psychedelic sector, Mike was co-founder and COO of Adelia Therapeutics (sold to CYBN) and a co-founder of Amorsa Therapeutics, which partnered with Johnson & Johnson to develop novel, ketamine based therapeutics for treatment resistant depression.
Michael’s scientific rigor and business acumen are foundational to the team’s ongoing innovation and growth.
Michael Palfreyman,
PhD
With more than 40 years of experience in biotech and pharma, Michael G. Palfreyman specializes in drug discovery, translational R&D, and early clinical development.
He is the holder of 53 patents and 150+ publications, and has led multiple companies to successful exits and partnerships. In the psychedelic sector, Mike was co-founder and COO of Adelia Therapeutics (sold to CYBN) and a co-founder of Amorsa Therapeutics, which partnered with Johnson & Johnson to develop novel, ketamine based therapeutics for treatment resistant depression.
Michael’s scientific rigor and business acumen are foundational to the team’s ongoing innovation and growth.
Brett J. Greene
Former Chief Innovation Officer at Cybin Inc. and co-founder/President/Chief Strategy Officer at Adelia Therapeutics (acquired by Cybin in 2020), Brett brings decades of experience in psychedelic and cannabinoid-based drug discovery and development.
Previously, he served as a research administrator at Northeastern University’s Center for Drug Discovery, contributing to groundbreaking advancements in the field.
Brett’s leadership and strategic insights have been pivotal in shaping innovative therapies and guiding companies through successful acquisitions.
Brett J. Greene
Former Chief Innovation Officer at Cybin Inc. and co-founder/President/Chief Strategy Officer at Adelia Therapeutics (acquired by Cybin in 2020), Brett brings decades of experience in psychedelic and cannabinoid-based drug discovery and development.
Previously, he served as a research administrator at Northeastern University’s Center for Drug Discovery, contributing to groundbreaking advancements in the field.
Brett’s leadership and strategic insights have been pivotal in shaping innovative therapies and guiding companies through successful acquisitions.
Brett J. Greene
Former Chief Innovation Officer at Cybin Inc. and co-founder/President/Chief Strategy Officer at Adelia Therapeutics (acquired by Cybin in 2020), Brett brings decades of experience in psychedelic and cannabinoid-based drug discovery and development.
Previously, he served as a research administrator at Northeastern University’s Center for Drug Discovery, contributing to groundbreaking advancements in the field.
Brett’s leadership and strategic insights have been pivotal in shaping innovative therapies and guiding companies through successful acquisitions.
Tommy MacLane
Tommy, a former Boston Red Sox player, has over a decade of experience in financial M&A advisory, guiding multi-industry transactions exceeding $100M.
As Senior Advisor at Endeavor Advisory Group, he specializes in capital raising for large-scale M&A deals.
Tommy’s combination of athletic discipline and financial expertise makes him a valuable strategist for the team’s growth.
Tommy MacLane
Tommy, a former Boston Red Sox player, has over a decade of experience in financial M&A advisory, guiding multi-industry transactions exceeding $100M.
As Senior Advisor at Endeavor Advisory Group, he specializes in capital raising for large-scale M&A deals.
Tommy’s combination of athletic discipline and financial expertise makes him a valuable strategist for the team’s growth.
Tommy MacLane
Tommy, a former Boston Red Sox player, has over a decade of experience in financial M&A advisory, guiding multi-industry transactions exceeding $100M.
As Senior Advisor at Endeavor Advisory Group, he specializes in capital raising for large-scale M&A deals.
Tommy’s combination of athletic discipline and financial expertise makes him a valuable strategist for the team’s growth.
Exclusive Strategic Alliance
MindMerge Advisors partners exclusively with Endeavor Advisory Group, expanding global reach and elevating our institutional capabilities for clients.
M&A Advisory
Comprehensive buy- and sell-side strategies, due diligence, and execution support for psychedelic pharma.
Comprehensive buy- and sell-side strategies, due diligence, and execution support for psychedelic pharma.
Comprehensive buy- and sell-side strategies, due diligence, and execution support for psychedelic pharma.
Financing
In conjunction with Endeavor Advisory Group, Mind Merge Advisors brings financing to qualifying clients.
In partnership with Endeavor Advisory Group, MindMerge Advisors brings financing solutions to qualifying clients.
Start the Conversation
Start the Conversation
Connect with our M&A experts
Connect with our M&A experts
Notice
Confidential and Proprietary
© 2025 MindMerge Advisors
All rights reserved
Notice
Confidential and Proprietary
© 2025 MindMerge Advisors
All rights reserved
Notice
Confidential and Proprietary
© 2025 MindMerge Advisors
All rights reserved